Other Vaccines - Egypt

Egypt

Highlights

The revenue in the Other Vaccines market in Egypt is projected to reach US$57.19m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 12.40%, resulting in a market volume of US$102.60m by 2029.
In global comparison, United States is expected to generate the highest revenue of US$24.73bn in 2024.
The demand for other vaccines in Egypt has been steadily increasing due to the country's proactive approach towards public health.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Other Vaccines in Egypt has been on the rise in recent years.

Customer preferences: Egypt has a large population, and with a growing middle class, there has been an increased demand for healthcare services, including vaccines. In addition, the government has been actively promoting vaccination campaigns, which has led to a rise in awareness and demand for vaccines.

Trends in the market: The Other Vaccines market in Egypt has been growing steadily over the past few years. The market is being driven by a number of factors, including an increase in the number of people seeking healthcare services, growing middle class, and government initiatives to promote vaccination campaigns. In addition, there has been a rise in the number of private healthcare providers in the country, which has led to increased competition and a wider range of vaccines being made available to consumers.

Local special circumstances: Egypt is a country with a high incidence of infectious diseases, including hepatitis, polio, and measles. As a result, there is a high demand for vaccines, particularly among children. The government has been actively promoting vaccination campaigns in order to prevent the spread of these diseases. In addition, the country has a large population of migrant workers, who are at a higher risk of contracting infectious diseases, which has further increased the demand for vaccines.

Underlying macroeconomic factors: The Egyptian economy has been growing steadily over the past few years, which has led to an increase in disposable income and a growing middle class. This has resulted in an increase in the demand for healthcare services, including vaccines. In addition, the government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services, including vaccines. The country has also been attracting foreign investment, which has led to an increase in the number of private healthcare providers in the country, which has further increased the availability of vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.